Key Points
- Michael Thomas Henderson, Apogee Therapeutics CEO, sold 20,000 shares on Jan. 14 at an average price of $81.11 for $1,622,200, leaving him with 1,192,987 shares (a 1.65% reduction from before the sale).
- Henderson has sold a total of 100,000 shares since mid-November (Nov. 13–Jan. 14), generating roughly $7.39 million in proceeds, signaling notable insider selling activity.
- Apogee shares trade near $80 (50‑day MA $73.44; 1‑year high $84.56) with a market cap of $5.52 billion, and analysts hold a consensus "Moderate Buy" rating with an average target of $104.27.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $81.11, for a total transaction of $1,622,200.00. Following the sale, the chief executive officer owned 1,192,987 shares of the company's stock, valued at $96,763,175.57. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Michael Thomas Henderson also recently made the following trade(s):
- On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.38, for a total transaction of $1,507,600.00.
- On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.01, for a total transaction of $3,000,400.00.
- On Thursday, November 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $63.01, for a total transaction of $1,260,200.00.
Apogee Therapeutics Price Performance
NASDAQ:APGE opened at $80.77 on Friday. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $84.56. The business has a fifty day moving average price of $73.44 and a 200-day moving average price of $53.12. The firm has a market capitalization of $5.52 billion, a price-to-earnings ratio of -18.44 and a beta of 1.41.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. On average, equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have weighed in on APGE shares. Craig Hallum reaffirmed a "buy" rating and set a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday, January 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Apogee Therapeutics in a research note on Wednesday, October 8th. Stifel Nicolaus set a $133.00 price target on Apogee Therapeutics in a research note on Tuesday, January 6th. Royal Bank Of Canada restated an "outperform" rating on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Finally, Wolfe Research began coverage on Apogee Therapeutics in a research report on Wednesday, January 7th. They set a "peer perform" rating for the company. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Apogee Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $104.27.
Read Our Latest Report on Apogee Therapeutics
Institutional Trading of Apogee Therapeutics
Several hedge funds have recently bought and sold shares of APGE. ANTIPODES PARTNERS Ltd grew its position in shares of Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock valued at $33,000 after purchasing an additional 246 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Apogee Therapeutics by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock valued at $77,000 after buying an additional 272 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Apogee Therapeutics by 99.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock valued at $33,000 after buying an additional 383 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company's stock worth $921,000 after acquiring an additional 694 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Apogee Therapeutics by 34.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company's stock worth $158,000 after acquiring an additional 941 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
